Tenon Medical, Inc.
TNONHealthcareNASDAQMedical Devices · Last scanned Jul 22, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Tenon Medical, Inc. focuses on Medical Devices services and products. Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. Valued at $3.5M, TNON is a micro-cap name in its sector. The company offers Catamaran SI-Joint Fusion System, an invasive inferior-posterior approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain.
Market Cap
$3.5M
Beta
1.36
P/E (TTM)
—
P/E (Fwd)
-0.33
EPS (TTM)
$-0.99
EPS (Fwd)
$-0.60
ROE
-220.3%
ROA
-55.4%
Cash
$4.6M
Total Debt
$4.9M
Free CF
-$6.1M
52W Change
-81.7%
Annual Financials
Cash vs Debt
Where TNON stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, TNON finished 74.03% below its 150-day moving average ($0.77) and 77.01% below its 200-day moving average ($0.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TNON overbought or oversold?
At the July 15, 2026 close, TNON's RSI(14) was 23.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Tenon Medical, Inc. carries $4.9M in total debt against $4.6M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$6.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -220.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $691K (2022) to $3.9M (2025), reflecting a 471% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing TNON's risk profile alongside its fundamentals and technical indicators provides a more complete picture.